» Articles » PMID: 14676128

Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2003 Dec 17
PMID 14676128
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We examined the effects of fenretinide [N-(4-hydroxyphenyl)retinamide; (4HPR)] on highly angiogenic Kaposi's sarcoma tumors in vivo and investigated the mechanisms involved for potential clinical applications.

Experimental Design: (CD-1)BR nude mice bearing KS-Imm cell tumors were randomized to receive 4HPR or vehicle until sacrifice. In vitro, KS-Imm and endothelial cells were treated with 4HPR to study the effects on proliferation, apoptosis, migration, and invasion; in vivo angiogenesis was evaluated in the Matrigel model. Angiogenesis-related and retinoid receptor molecules were examined at the mRNA and protein expression levels.

Results: In vivo, 4HPR significantly (P<0.001) reduced growth of detectable Kaposi's sarcoma (KS) xenografts and inhibited angiogenesis in the Matrigel plug assay (P<0.04). In vitro, 4HPR affected KS-Imm and endothelial cell growth and KS-Imm migration and invasion. 4HPR invasion inhibition was associated with decreased release of matrix metalloprotease-2 and rapid reduction of vascular endothelial growth factor (VEGF) expression by KS cells and of vascular endothelial growth factor receptor 2 (VEGFR2) by KS and endothelial cells. Finally, 4HPR repression of angiogenesis was associated with a 4HPR-induced increase in retinoic acid receptor beta expression.

Conclusions: These data indicate that 4HPR inhibits KS tumor growth in vivo through a mechanism involving the modulation of angiogenesis-associated growth factors and their receptors on both tumor and endothelial cells. In addition, 4HPR inhibited invasion by decreasing of matrix metalloprotease-2 activity. Our results justify further studies to evaluate the utility of 4HPR as a chemopreventive or therapeutic agent in KS, a malignancy associated with immune suppression that has a high risk of recurrence with highly active antiretroviral therapy failure.

Citing Articles

The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review.

Ramchatesingh B, Martinez Villarreal A, Arcuri D, Lagace F, Setah S, Touma F Int J Mol Sci. 2022; 23(20).

PMID: 36293471 PMC: 9603842. DOI: 10.3390/ijms232012622.


Fenretinide reduces angiogenesis by downregulating CDH5, FOXM1 and eNOS genes and suppressing microRNA-10b.

Yucel E, Sahin M Mol Biol Rep. 2020; 47(3):1649-1658.

PMID: 31925643 DOI: 10.1007/s11033-020-05252-6.


Fenretinide Perturbs Focal Adhesion Kinase in Premalignant and Malignant Human Oral Keratinocytes. Fenretinide's Chemopreventive Mechanisms Include ECM Interactions.

Han B, Li S, Tong M, Holpuch A, Spinney R, Wang D Cancer Prev Res (Phila). 2015; 8(5):419-30.

PMID: 25712051 PMC: 4417376. DOI: 10.1158/1940-6207.CAPR-14-0418.


E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα.

Zhang L, Zhou Q, Zhang N, Li W, Ying M, Ding W Cell Cycle. 2014; 13(8):1277-87.

PMID: 24608861 PMC: 4049964. DOI: 10.4161/cc.28190.


Dangerous liaisons: molecular basis for a syndemic relationship between Kaposi's sarcoma and P. falciparum malaria.

Conant K, Marinelli A, Kaleeba J Front Microbiol. 2013; 4:35.

PMID: 23487416 PMC: 3594938. DOI: 10.3389/fmicb.2013.00035.